John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) President John Volpone sold 24,576 shares of X4 Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the transaction, the president owned 265,305 shares of the company’s stock, valued at $1,177,954.20. This represents a 8.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR remained flat at $4.29 on Thursday. 1,126,769 shares of the company’s stock traded hands, compared to its average volume of 562,019. X4 Pharmaceuticals, Inc. has a 12 month low of $2.45 and a 12 month high of $4.83. The firm has a fifty day simple moving average of $4.04 and a 200-day simple moving average of $3.96. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The firm has a market cap of $425.35 million, a P/E ratio of -3.57 and a beta of 0.37.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The business had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. As a group, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the last quarter. Rhumbline Advisers grew its stake in X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after buying an additional 9,690 shares during the last quarter. Jane Street Group LLC grew its stake in X4 Pharmaceuticals by 112.5% during the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after buying an additional 51,544 shares during the last quarter. Vanguard Group Inc. increased its position in X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after buying an additional 178,593 shares during the period. Finally, Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the third quarter worth approximately $47,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on XFOR shares. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 target price on the stock. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.